Actively Recruiting

Phase 2
Age: 18Years - 120Years
MALE
NCT05616650

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Led by National Cancer Institute (NCI) · Updated on 2026-04-29

42

Participants Needed

1

Research Sites

267 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Many people now seek out focal therapy options to decrease the side effects of treatment. Until now, several forms of physical destruction with heat (thermal ablation), cold (cryotherapy), sound waves (HIFU), laser (FLA), and electrical energy (IRE). A new type of radiation (SBRT) may be an effective way to cure men of early-stage prostate cancer with fewer side effects than standard treatments. Objective: To see how people with untreated localized prostate cancer will respond to focal therapy with SBRT. Eligibility: People aged 18 years and older with untreated localized prostate cancer (prostate cancer which has not spread outside of the prostate gland). Design: * Participants will undergo screening including blood tests, an MRI, a PSMA PET/CT (18F-DCFPyL), and a biopsy. * Small, non-radioactive, gold seeds about the size of a grain of rice will be placed in and/or around the tumor to help target the radiation treatment. * Radiation (SBRT) will occur in 2 separate sessions about 1 week apart. No sedation is used, these sessions are painless. Each session will take about 1-2 hours. Participants can go home afterwards. * Follow-up will continue for 2 years with repeat scans (MRI and PSMA PET/CT) and blood (PSA) tests. * After two years, a biopsy will be done to understand the impact of this new treatment on prostate cancer.

CONDITIONS

Official Title

Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor

Who Can Participate

Age: 18Years - 120Years
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed low or intermediate risk prostate adenocarcinoma verified by biopsy
  • Single focus of prostate cancer on MRI and PSMA PET/CT imaging confirmed by targeted biopsy
  • Age 18 years or older
  • ECOG performance status 0 to 2 (Karnofsky score greater than 60%)
  • Male participants must agree to use effective contraception during the study and for 120 days after last radiation
  • Ability to understand and provide written informed consent
Not Eligible

You will not qualify if you...

  • High-risk prostate cancer features (Gleason score 8 or higher, clinical stage greater than cT2c, or PSA 20 ng/mL or higher)
  • Biopsy showing grade group 2 or higher adenocarcinoma outside the visible tumor lesion
  • Planned or current systemic androgen deprivation therapy or chemotherapy
  • Receiving any other investigational agents
  • Pelvic or distant metastases found on staging studies
  • AUA-SI/IPSS urinary symptom score greater than 18
  • Previous curative treatment for prostate cancer
  • Active urinary tract infection
  • Untreated or uncontrolled HIV, hepatitis B, or hepatitis C infections
  • Tumor location unsuitable for planned treatment
  • Connective tissue diseases or radiation hypersensitivity syndromes
  • Active inflammatory bowel disease within the radiation field
  • Prior medical or surgical history in the pelvis increasing risk of radiation toxicity
  • Inability or unwillingness to undergo contrast-enhanced MRI or 18F-DCFPyL PET/CT
  • Allergy to 18F-DCFPyL tracer or contraindication to fiducial marker implantation
  • History of prior overlapping radiotherapy
  • Uncontrolled illness or social situations limiting study compliance

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

National Institutes of Health Clinical Center

Bethesda, Maryland, United States, 20892

Actively Recruiting

Loading map...

Research Team

D

Debbie-Ann N Nathan, R.N.

CONTACT

D

Deborah E Citrin, M.D.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here